Literature DB >> 30726558

Diagnostic accuracy of dobutamine stress echocardiography in the detection of cardiac allograft vasculopathy in heart transplant recipients: A systematic review and meta-analysis study.

Ahmed Elkaryoni1, Ghada Abu-Sheasha2, Ahmed M Altibi3, Adil Hassan1, Karim Ellakany4, Navin C Nanda5.   

Abstract

BACKGROUND: Dobutamine stress echocardiography (DSE) is a well-established imaging modality used to screen patients with mild-to-moderate risk for coronary artery disease. In heart transplantation recipients, cardiac allograft vasculopathy (CAV) is a common and lethal complication. The use of DSE to detect CAV showed promising results initially, but later studies showed limitation in its use to detect CAV. It is unclear if this cohort of patients derives benefit from DSE.
METHODS: We searched PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and Scopus from inception through March 2018 for studies examining the accuracy of DSE in correlation to coronary angiography (CA) or intravascular ultrasound (IVUS) to detect CAV. Original studies comparing the ability of DSE to detect CAV in comparison with CA or IVUS were included. Relevant data were extracted and hierarchical summary receiver operating characteristic analysis was conducted to test the overall diagnostic accuracy of DSE for patients with CAV.
RESULTS: Eleven studies (749 participants) met the inclusion criteria. The sensitivity of DSE varied from 1.7% to 93.8%, and specificity, from 54.8% to 98.8%. Pooled sensitivity was 60.2% (95% confidence interval (CI), 33.0%-82.3%) and specificity 85.7% (95% CI, 73.8%-92.7%). DSE had an overall diagnostic odds ratio (OR) of 9.1 (95% CI, 4.6-17.8), positive likelihood ratio (LR+) of 4.1 (95% CI, 2.8-6.1), negative likelihood ratio (LR-) of 0.47 (95% CI: 0.23-0.73), and area under curve (AUC) of 0.73 (95% CI, 0.72-0.75). Heterogeneity among studies was not statistically significant (τ2  = 0.32, Cochran's Q = 9.5, P = 0.483).
CONCLUSION: Dobutamine stress echocardiography has a limited sensitivity to detect early CAV but its specificity is much higher. There remains a need for an alternative noninvasive modality which will have both high sensitivity and high specificity for detecting CAV.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac allograft vasculopathy; coronary angiography; diagnostic accuracy; dobutamine stress echocardiography; heart transplantation; intravascular ultrasound

Mesh:

Substances:

Year:  2019        PMID: 30726558     DOI: 10.1111/echo.14268

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  5 in total

Review 1.  Cardiac Allograft Injuries: A Review of Approaches to a Common Dilemma, With Emphasis on Emerging Techniques.

Authors:  Christopher Hayward
Journal:  Int J Heart Fail       Date:  2022-04-06

Review 2.  PET Myocardial Blood Flow for Post-transplant Surveillance and Cardiac Allograft Vasculopathy in Heart Transplant Recipients.

Authors:  Attila Feher; Edward J Miller
Journal:  Curr Cardiol Rep       Date:  2022-10-24       Impact factor: 3.955

Review 3.  The role of non-invasive imaging modalities in cardiac allograft vasculopathy: an updated focus on current evidences.

Authors:  C Sciaccaluga; N Ghionzoli; G E Mandoli; N Sisti; F D'Ascenzi; M Focardi; S Bernazzali; G Vergaro; M Emdin; S Valente; M Cameli
Journal:  Heart Fail Rev       Date:  2021-08-12       Impact factor: 4.654

4.  Diagnostic Accuracy of Dobutamine Stress Echocardiography for Detection of Cardiac Allograft Vasculopathy in Orthotopic Heart Transplant Patients.

Authors:  Mohammed Mahmoodurrahman; Josef Marek; Hamzah Ruxshan Juhardeen; Talal Al Otaibi; Vera Maria Cury Salemi; Najmeddine Echahidi; Jehad Al Buraiki; Bahaa M Fadel; Dania Mohty
Journal:  J Saudi Heart Assoc       Date:  2021-10-15

Review 5.  Evaluation of cardiac allograft vasculopathy by positron emission tomography.

Authors:  Attila Feher; Albert J Sinusas
Journal:  J Nucl Cardiol       Date:  2021-01-03       Impact factor: 5.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.